GIA
NVCR icon

Gladstone Institutional Advisory’s NovoCure NVCR Stock Holding History

Gladstone Institutional Advisory’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,575
Closed -$349K – 584
2021
Q2 		$349K Sell
1,575
-25
-2% -$4.86K 0.04% 368
2021
Q1 		$211K Hold
1,600
– – 0.03% 376
2020
Q4 		$277K Buy
+1,600
New +$219K 0.06% 239

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gladstone Institutional Advisory's NVCR Position: Q3 2021 in Review

Gladstone Institutional Advisory sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,575 shares — an estimated $349K sold.

Gladstone Institutional Advisory first reported a position in NVCR in Q4 2020 and held it in 3 quarters. The position peaked at $349K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Gladstone Institutional Advisory reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 1,575 NovoCure shares in Q3 2021, an estimated $349K.
  • Gladstone Institutional Advisory first reported a position in NovoCure in Q4 2020 and held it in 3 quarters.
  • Gladstone Institutional Advisory's NovoCure position peaked at $349K in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Gladstone Institutional Advisory's 13F filing for Q3 2021, filed 15 Nov 2021.